Investment opportunity

We at Continuum truly believe that our work will help millions of people around the globe.
We invite you to join us by making a difference.

WHAT YOUR INVESTMENT WILL HELP FUND

  Increased investment in, and strengthening of, existing research teams

  Increase to 20, the number of participating research institutions (including USA and Europe)

• Acquisition of the latest technology

 Completing the creation of an International Scientific Advisory Board

 Company Board

 Creation of an Ethics Board

 Acquisition of bespoke product laboratories

 Establish and run Clinical Trials

 Expand research portfolio into Monoclonal antibodies, Neo-antigens, Cytokines and Checkpoint inhibitors

 The establishment of a bespoke Continuum Research Centre; recruiting the world-leading scientists to work with Continuum leadership (location to be decided)

 Commencement of final phase trials

IMMUNO-ONCOLOGY MARKET TRENDS MAKE A COMPELLING INVESTMENT CASE

  Current market size estimated at $8,333 million

  Immuno-oncology market size estimated to grow at a CAGR 21.5% from 2017 to 2025 (Polaris Market Research)

  Goldman Sachs values IO market at around $140 billion

  From 2015 the personalised medical market has grown by 40% to approx.
$1.76 trillion and by 2020 the market will be worth $2.7 trillion

(Source: Business Wire Nov 2018 & Polaris Market Watch)

RECENT M&A ACTIVITY IN THE BIOTECH SECTOR

In fulfilling its aims and objectives Continuum will save and enhance the lives of millions. It will, based on recent M&A activity in the Biotech sector as shown here, also deliver potentially significant financial returns.

  Gilead aquires Kite (CD19 CAR company) for $11.9 billion

  Celgene acquired Impact Biomedicines for around $7 billion

  Celgene acquired Juno Therapeutics for a total of approx. $9 billion

  Sanofi completed its $11.6 billion purchase of Bioveratis

  Sanofi completed the $4.6 billion purchase of Ablynx

  Novartis acquired the $8.7 billion acquisition of AveXis

  Glaxo Smith Kline $9.2 billion deal to take full control of healthcare
joint venture with Novartis

  Bristol-Myers Squibb to acquire Celgene for $74 billion

Join us in the fight against cancer now, with an investment that will make a difference.